

NEXTLEAF SOLUTIONS Ltd.

11:58 05 Nov 2020

Nextleaf Solutions wins second US patent for the acetylation of cannabinoids

Nextleaf Solutions Ltd (CSE:OILS) (OTCQB:OILFF) has won another patent.

In a statement Thursday, the company said the US Patent and Trademark Office granted it a second patent for the acetylation of cannabinoids. More specifically, the patent covers a process for acetylating cannabidiol (CBD), and subsequent refinement of CBO-O-Acetate.

Nextleaf said it owns a portfolio of 10-issued US patents for extraction, purification, and delivery of cannabinoids, along with a 100% success rate obtaining issued patents from its pending patent applications, compared to less than 50% for life science companies.

READ: Nextleaf Solutions completes successful scale trials for its rapid emulsion technology

"We expect the results of the 2020 US elections will have a transformational effect on the future of cannabis legalization in the United States," said CEO Paul Pedersen. "With the second largest patent portfolio of any cannabis company, Nextleaf has the type of robust intellectual property that draws attention from pharmaceutical companies anticipating the U.S. federal legalization of cannabinoids."

Nextleaf said its patented process to produce CBD-O-Acetate enables the standardization of a more potent analog of CBD, an alternative option to experience the unique medicinal benefits associated with targeted drug delivery. Prodrugs utilize various physical and chemical modifications to improve features of active drugs. Maintaining the integrity of the molecule and its ability to deliver drugs to precisely targeted areas in the body may increase efficacy for desired outcomes.

The company believes an orally consumable CBD metabolic prodrug produced under its patented process for acetylating cannabidiol will enhance the therapeutic potency of CBD.

Nextleaf was granted a US patent in February for the acetylation of delta 9-tetrahydrocannabinol (THC), and subsequent refinement of THC-O-Acetate.

"With this second US patent for acetylation of cannabinoids, we are able to efficiently modify and potentially improve upon the medicinal properties of a natural product that has been in use for thousands of years," said Ryan Ko, chief technical officer.

Nextleaf said it has commenced a search for commercialization partners of its cannabinoid acetylation patents, with a specific focus on pharmaceutical companies seeking novel cannabinoid-derived products for clinical trials, and turnkey pharmaceutical production.

Price: 0.29

Market Cap: \$34.95 m

1 Year Share Price Graph



Share Information

Code: OILS

Listing: CSE

52 week High Low
0.42 0.14

Sector: Cannabis

Website: www.nextleafsolutions.com

Company Synopsis:

Nextleaf is an innovative cannabis processor that owns one of the largest portfolios of U. S. patents for the extraction, purification, and delivery of cannabinoids. The Company is a low-cost producer of cannabis distillate and private label THC & CBD oils through its wholly-owned subsidiary Nextleaf Labs Ltd.

action@proactiveinvestors.com

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter [@PatrickMGraham](https://twitter.com/PatrickMGraham)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of NEXTLEAF SOLUTIONS Ltd. named herein, including the promotion by the Company of NEXTLEAF SOLUTIONS Ltd. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).